Study identifier:D4200C00008
ClinicalTrials.gov identifier:NCT00098345
EudraCT identifier:N/A
CTIS identifier:N/A
An Open Label, Two Stage, Phase II Study to Evaluate the Efficacy and Tolerability of ZD6474 in Patients with Locally Advanced or Metastatic Hereditary Medullary Thyroid Carcinoma.
Thyroid Cancer
Phase 2
No
ZD6474 (vandetanib)
All
40
Interventional
18 Years - 130 Years
Allocation: N/A
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Mar 2016 by AstraZeneca
AstraZeneca
-
The purpose of this open label, two stage, phase II study is to evaluate the efficacy and tolerability of ZD6474 in patients with locally advanced or metastatic hereditary medullary thyroid carcinoma.
Location
Location
Villejuif Cedex, France
Location
Durham, NC, United States
Location
New Haven, CT, United States
Location
San Francisco, CA, United States
Location
New York, NY, United States
Location
Houston, TX, United States
Arms | Assigned Interventions |
---|---|
Experimental: Caprelsa (vandetanib) 300 mg Daily oral dose of Caprelsa (vandetanib) 300mg | Drug: ZD6474 (vandetanib) oral once daily tablet Other Name: Caprelsa™ (vandetanib) |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.